ELI LILLY AND COMPANY Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
ELI LILLY AND COMPANY (LLY) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $5.13 billion as of 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2018-04-27
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $5.13B.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $4.69B.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $4.01B.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $3.98B.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2018-03-31 | $5.13B 10-Q · filed 2018-04-27 |
| 2017-12-31 | $4.69B 10-Q · filed 2018-04-27 |
| 2017-09-30 | $4.01B 10-Q · filed 2017-10-27 |
| 2017-06-30 | $3.98B 10-Q · filed 2017-07-28 |
| 2017-03-31 | $3.03B 10-Q · filed 2017-05-01 |
| 2016-12-31 | $3.26B 10-K · filed 2018-02-20 |
| 2016-09-30 | $1.27B 10-Q · filed 2016-10-28 |
| 2016-06-30 | $769.90M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $1.37B 10-Q · filed 2016-04-29 |
| 2015-12-31 | $2.93B 10-K · filed 2017-02-21 |
| 2015-09-30 | $2.37B 10-Q · filed 2015-10-30 |
| 2015-06-30 | $2.29B 10-Q · filed 2015-07-30 |
| 2015-03-31 | $2.05B 10-Q · filed 2015-04-30 |
| 2014-12-31 | $3.13B 10-K · filed 2016-02-19 |
| 2014-09-30 | $3.98B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $1.77B 10-Q · filed 2014-07-28 |
| 2014-03-31 | $2.61B 10-Q · filed 2014-04-28 |
| 2013-12-31 | $3.66B 10-K · filed 2015-02-19 |
| 2013-09-30 | $3.44B 10-Q · filed 2013-10-30 |
| 2013-06-30 | $4.30B 10-Q · filed 2013-07-26 |
| 2013-03-31 | $1.71B 10-Q · filed 2013-04-26 |
| 2012-12-31 | $2.10B 10-K · filed 2014-02-19 |
| 2012-09-30 | $942.30M 10-Q · filed 2012-10-26 |
| 2012-06-30 | $1.47B 10-Q · filed 2012-07-27 |
| 2012-03-31 | $1.88B 10-Q · filed 2012-04-30 |
| 2011-12-31 | $2.16B 10-K · filed 2013-02-21 |
| 2011-09-30 | $1.65B 10-Q · filed 2011-10-28 |
| 2011-06-30 | $1.34B 10-Q · filed 2011-07-29 |
| 2011-03-31 | $764.90M 10-Q · filed 2011-04-29 |
| 2010-12-31 | $758.10M 10-K · filed 2012-02-24 |
| 2010-09-30 | $322.20M 10-Q · filed 2010-10-29 |
| 2010-06-30 | $292.40M 10-Q/A · filed 2010-08-02 |
| 2009-12-31 | $449.40M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |